August 2, 2021 -- T-Knife Therapeutics has secured $110 million in funding that it plans to use to further develop its T-cell receptor engineered T-cell therapies (TCR-T).
T-Knife has used its proprietary human TCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. Specifically, the company will use the financing to begin a phase I/II clinical study of TK-8001, a TCR-T cell therapy for melanoma-associated antigen 1 (MAGE-A1) positive solid tumors in the fourth quarter of this year, it said.
The series B funding round was led by Fidelity Management and Research, with participation from LSP, Qatar Investment Authority, Casdin Capital, Sixty Degree Capital, and CaaS Capital.
Copyright © 2021 scienceboard.net